[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603032":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":25,"responsibleParty":42,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":58,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"First Affiliated Hospital of Fujian Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Suspected PH by Echocardiography",null,"This study includes a prospective observational cohort of patients with suspected pulmonary hypertension (PH), identified by transthoracic echocardiography (TTE) showing a pulmonary artery systolic pressure (PASP) ≥35 mmHg. No experimental intervention will be applied. Participants will undergo comprehensive data collection, including echocardiography, cardiac magnetic resonance imaging (CMR), electrocardiography (ECG), laboratory testing, and biospecimen sampling (blood, urine, and stool). Follow-up will occur every 6 months for up to 3 years to record clinical outcomes and support the development of a dynamic, multimodal risk prediction model based on artificial intelligence.",[13],{"name":14,"affiliation":5,"role":15},"Dajun Chai, MD","PRINCIPAL_INVESTIGATOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","0086059187981637","dajunchai-fy@fjmu.edu.cn",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Biyun Chen, MSc","008613876168899","heraty@sina.com",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"The First Affiliated Hospital of Fujian Medical University","RECRUITING","Fuzhou","Fujian","350011","China","CN",{"type":35,"coordinates":36},"Point",[37,38],119.30611,26.06139,{"lat":38,"lon":37},[41],{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},{"type":15,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Dajun Chai","Professor and Chief Physician, Department of Cardiology","100603032","ph-dypred-a-multimodal-dynamic-risk-prediction-study-in-pulmonary-hypertension-100603032",false,"NCT07131241","PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary Hypertension","Research on Dynamic Risk Prediction for Patients With Pulmonary Hypertension Based on Multimodal Data Fusion: A Prospective Observational Study","PH-DyPred","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Pulmonary artery systolic pressure (PASP) ≥35 mmHg as estimated by echocardiography\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Severe hepatic or renal insufficiency\n* Malignancy under active treatment\n* Severe infection\n* Active autoimmune disease\n* Major surgery within the past 3 months\n* Pregnant or breastfeeding women\n* Severe psychiatric disorder impairing ability to comply with the study protocol","ALL","18 Years",{"count":56,"type":57},1000,"ESTIMATED","2 Years","OBSERVATIONAL","Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by elevated pulmonary artery pressure and vascular remodeling, which leads to right heart failure and increased mortality. Despite advances in diagnostics, risk stratification remains limited due to the disease's heterogeneity. This study aims to develop and validate a dynamic risk prediction model for PH by integrating multimodal data-including echocardiography, Cardiac MRI, PET-MR, ECG, biomarkers, and clinical features-using advanced machine learning algorithms. The study will establish a prospective cohort of PH patients to explore predictive markers, stratify prognosis, and provide a scientific basis for early warning and individualized management.",[62],"Pulmonary Hypertension",[62,64,65,66,67,68],"Dynamic Risk Prediction","Multimodal Data Fusion","Echocardiography","Right Heart Function","Cardiac Magnetic Resonance","2025-08-27",{"date":71,"type":72},"2025-08-28","ACTUAL",{"date":74,"type":72},"2025-06-27",{"date":76,"type":57},"2029-06-30",{"name":5,"class":6},1]